Echelon Capital Markets analyst Stefan Quenneville stayed bullish on Medexus Pharmaceuticals in a Thursday update to clients and maintained a Speculative Buy rating on the stock.
After reviewing the latest quarterly results from Medexus Pharmaceuticals, Roth Capital Partners analyst Scott R. Henry is sticking with a bullish call on the stock.
Strong quarterly revenue looks good on Medexus Pharmaceuticals, according to Raymond James analyst Rahul Sarugaser, who reviewed the company’s latest quarter in an update to clients on Thursday.
Québec-based specialty pharma company Medexus Pharmaceuticals received a target price increase from Raymond James on Thursday after securing a new bank debt.